Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

• Status: NOT_YET_RECRUITING
• Trial end date: 2031-03-31

Summary

The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.

• Phase: PHASE1

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: Exelixis
• Treatments: Ipilimumab; Nivolumab